Several members and affiliates of the LaMontagne Center have been publishing research related to COVID-19.

LCID Member Papers 
In scientific journals, preprints, etc.

• CL Hsieh, JS McLellan. Protein engineering responses to the COVID-19 pandemic. Current Opinion in Structural Biology, 102385. June 2022 edition.

• AD Dang, TD Vu, HH Vu, AT Van Pham, MTN Dang, B Van Le, TH Duong, ... JS McLellan, ... Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1 …Vaccine. May 14, 2022. (In press, corrected proof).

• EE Escobar, S Wang, R Goswami, MB Lanzillotti, L Li, JS McLellan, ... Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry. Analytical Chemistry. Apr 7, 2022.

• AR Shiakolas, KJ Kramer, NV Johnson, SC Wall, N Suryadevara, ... JS McLellan... Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nature Biotechnology, 1-6. Mar 3, 2022.

• SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, C-L Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nat Struct Mol Biol. 2 March 2022.

• P Pitisuttithum, V Luvira, S Lawpoolsri, S Muangnoicharoen, JA Maynard, JS McLellan, JE Pak, S Marqusee. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase … EClinicalMedicine 45, 101323. Mar 1, 2022.

• SR Shoemaker, SM Costello, HT Hobbs, AW Nguyen, CL Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike protein reversibly samples an open-trimer conformation exposing novel epitopes. Biophysical Journal 121 (3), 29a. Feb 20, 2022

• N Li, B Zhao, R Stavins, A Sol Peinetti, N Chauhan, R Bashir, BT Cunningham, WP King, Y Lu, E Valera, X Wang. Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing. Cur. Opin. Solid State & Material Science, 26, 100966. Feb 2022.

• H Chawla, SE Jossi, SE Faustini, F Samsudin, JD Allen, Y Watanabe, ML Newby, E Marcial-Juárez, RE Lamerton, JS McLellan, PJ Bond, AG Richter, AF Cunningham, M Crispin. Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike mimetic. Journal of molecular biology 434 (2), 167332. Jan 30, 2022.

• K Javanmardi, TH Segall-Shapiro, CW Chou, DR Boutz, RJ Olsen, X Xie, ... AD Ellington. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. bioRxiv. Jan 1, 2022.

• H Chawla, SE Jossi, SE Faustini, F Samsudin, JD Allen, Y Watanabe, ML Newby, E Marcial-Juárez, RE Lamerton, JS McLellan, PJ Bond, AG Richter, AF Cunningham, M Crispin. Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike mimetic. Journal of molecular biology 434 (2), 167332, 2022.

• JJ Lavinder, GC Ippolito. Boosted immunity to the common cold might protect children from COVID-19. Nat Immunol. Dec 21, 2021.

• ​ C-L Hsieh, AP Werner, SR Leist, et al with BS Graham, KS Corbett, JS McLellan. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports. 2021 Nov 2. DOI: doi.org/10.1016/j.celrep.2021.109929.

• CD Swaim, Y-C Perng, X Zhao, LA Canadeo, HH Harastani, TL Darling, ACM Boon, DJ Lenschow, and JM Huibregtse.  6-Thioguanine Blocks SARS-CoV-2 Replication by Inhibition of PLpro. iScience. Volume 24, Issue 10, 22 October 2021, 103213.

• P Kaplonek, C Wang, Y Bartsch, S Fischinger, MJ Gorman, K Bowman, J Kang, D Dayal, P Martin, RP Nowak, A-C Villani, C-L Hsieh, NC Charland, ALK Gonye, I Gushterova, HK Khanna, TJ LaSalle, KM Lavin-Parsons, BM Lilley, CL Lodenstein, K Manakongtreecheep, JD Margolin, BN McKaig, M Rojas-Lopez, BC Russo, N Sharma, J Tantivit, MF Thomas, M Sade-Feldman, J Feldman, B Julg, EJ Nilles, ER Musk, AS Menon, ES Fischer, JS McLellan, A Schmidt, MB Goldberg, MR Filbin, N Hacohen, DA Lauffenburger, G Alter. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology 6 (64), eabj2901. October 15, 2021.

• JM Schaub, C-W Chou, H-C Kuo, K Javanmardi, C-L Hsieh,  JA Goldsmith, AM DiVenere, KC Le, D Wrapp, PO Byrne, CK Hjorth, NV Johnson, J Ludes-Meyers, AW Nguyen, N Wang, JJ Lavinder, GC Ippolito, JA Maynard, JS McLellan, IJ Finkelstein. Expression and characterization of SARS-CoV-2 spike protein. Nature Protocols. October 5, 2021.

• KJ Kramer, NV Johnson, AR Shiakolas, et al with  JE Crowe Jr, A Bukreyev, RH Carnahan, JS McLellan, IS Georgiev. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports. October 5, 2021. DOI: doi.org/10.1016/j.celrep.2021.109784.

• D Haslwanter, ME Dieterle, AZ Wec, CM O’Brien, M Sakharka, C Florez, K Tong, CG Rappazzo, G Lasso, O Vergnolle, AS Wirchnianski, RH Bortz II, E Laudermilch, JM Fels, A Mengotto, RJ Malonis, GI Georgiev, JA Quiroz, D Wrapp, N Wang, KE Dye, J Barnhill, JM Dye, JS McLellan, JP Daily, JR Lai, AS Herbert, LM Walker, K Chandran, and RK Jangra. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. mBio. October 5, 2021. DOI: doi.org/10.1128/mBio.02473-21.

• N Li, B Zhao, R Stavins, AS Peinetti, N Chauhan, R Bashir, BT Cunningham, WP King, Y Lu, E Valera, X Wang. Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing. Cur. Opin. Solid State & Material Science, 26, 100966 (2021).

• AS Peinetti, RJ Lake, W Cong, L Cooper, Y Wu, Yu Ma, GT Pawel, ME Toimil-Molares, C Trautmann, L Rong, B Mariñas, O Azzaroni, and Y Lu. Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. Sci. Adv. 7, eabh2848. 22 Sept. 2021.

• E Andreano, G Piccini, D Licastro, L Casalino, NV Johnson, I Paciello, S Dal Monego, E Pantano, N Manganaro, A Manenti, R Manna, E Casa, I Hyseni, L Benincasa, E Montomoli, RE Amaro, JS McLellan, and R Rappuoli. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. PNAS. September 7, 2021. 118 (36) e2103154118; DOI: doi.org/10.1073/pnas.2103154118.

• J Goldsmith, AM DiVenere, JA Maynard, JS McLellan. Structural basis for antibody binding to adenylate cyclase toxin reveals RTX-linkers as key neutralization-sensitive epitopes. Plos Pathogens 17(9): e1009920. September 21, 2021.

• MPACC Manuscript Writing Team; IMPACC Network Steering Committee. N Rouphael, H Maecker, RR Montgomery, J Diray-Arce, SH Kleinstein, MC Altman, SE Bosinger, W Eckalbar, L Guan, CL Hough, F Krammer, C Langelier, O Levy, K McEnaney, B Peters, A Rahman, JV Rajan, S Sigelman, H Steen, H van Bakel, A Ward, MR Wilson, P Woodruff, CR Zamecnik, AD Augustine, A Ozonoff, EF Reed, PM Becker, N Agudelo Higuita, MC Altman, MA Atkinson, LR Baden, PM Becker, C Bime, SC Brakenridge, CS Calfee, CB Cairns, D Corry, MM Davis, AD Augustine, LIR Ehrlich, EK Haddad, DJ Erle, A Fernandez-Sesma, DA Hafler, CL Hough, F Kheradmand, SH Kleinstein, M Kraft, O Levy, GA McComsey, E Melamed, W Messer, J Metcalf, RR Montgomery, KC Nadeau, A Ozonoff, B Peters, B Pulendran, EF Reed, N Rouphael, M Sarwal, J Schaenman, R Sekaly, AC Shaw, V Simon. (2021). Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Sci Immunol. 6(62). doi: 10.1126/sciimmunol.abf3733. PubMed PMID: 34376480. Aug 10, 2021.

• SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, C-L Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. bioRxiv 2021.07.11.451855; DOI: doi.org/10.1101/2021.07.11.451855 (Preprint).

• X Wang, Z Du, KE Johnson, RF Pasco, SJ Fox, M Lachmann, JS McLellan, and LA Meyers. Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States. Emerging Infectious Diseases. Volume 27, Number 7—July 2021.

• MD Hall, JM Anderson, A Anderson, D Baker, J Bradner, KR Brimacombe, EA Campbell, KS Corbett, K Carter, S Cherry, L Chiang, T Cihlar, E De Wit, M Denison, M Disney, CV Fletcher, SL Ford-Scheimer, M Götte, AC Grossman, FG Hayden, DJ Hazuda, CA Lanteri, H Marston, AD Mesecar, S Moore, JO Nwankwo, J O’Rear, G Painter, K Singh Saikatendu, CA Schiffer, TP Sheahan, P-Y Shi, HD Smyth, MJ Sofia, M Weetall, SK Weller, R Whitley, AS Fauci, CP Austin, FS Collins, AJ Conley, MI Davis. Report of the national institutes of health SARS-CoV-2 antiviral therapeutics summit. The Journal of infectious diseases 224 (Supplement_1), S1-S2192021. June 10, 2021.

• WN Voss, YJ Hou, NV Johnson, G Delidakis, JE Kim , K Javanmardi, AP Horton, F Bartzoka, CJ Paresi, Y Tanno, C-W Chou, SA Abbasi, W Pickens, K George, DR Boutz, DM Towers, JR McDaniel, D Billick, J Goike, L Rowe, D Batra, J Pohl, J Lee, S Gangappa, S Sambhara, M Gadush, N Wang, MD Person, BL Iverson, JD Gollihar, J Dye , A Herbert, IJ Finkelstein, RS Baric, JS McLellan, G Georgiou, JJ Lavinder, GC Ippolito. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science. June 4, 2021. 372(6546):1108-1112. DOI: 10.1126/science.abg5268. PMID: 33947773.

• AR Shiakolas, KJ Kramer, Dl Wrapp, SI Richardson, A Schäfer, S Wall, N Wang, K Janowska, KA Pilewski, R Venkat, R Parks, NP Manamela, N Raju, E Friedman Fechter, CM Holt, N Suryadevara, RE Chen, DR Martinez, RS Nargi, RE Sutton, JE Ledgerwood, BS Graham, MS Diamond, BF Haynes, P Acharya, RH Carnahan, JE Crowe Jr, RS Baric, L Morris, JS McLellan, IS Georgie. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine 2 (6), 100313. June 2021.

• T Li, W Xue, Q Zheng, S Song, C Yang, HL Xiong, S Zhang, M Hong, YL Zhang, H Yu, Y Zhang, H Sun, Y Huang, T Deng, X Chi, J Li, S Wang, L Zhou, T Chen, Y Wang, T Cheng, T-Y Zhang, Q Yuan, Q Zhao, J Zhang, J McLellan, Z Hong Zhou, Z Zhang, Y Gu, S Li, N Xia. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist to circulating variants. Research Square (Preprint). June 2021.

• PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ... McLellan, JS, ... Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594 (7862), 253-258. June 2021.

• S Bhadra, TE Riedel, S Lakhotia, ND Tran, AD Ellington. High-surety isothermal amplification and detection of SARS-CoV-2. Msphere 6 (3), e00911-2072021. May 19, 2021.

• BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... McLellan, JS, ... The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science translational medicine 13 (593). May 12, 2021.

• M Sakharkar, CG Rappazzo, WF Wieland-Alter, CL Hsieh, D Wrapp, ... JS McLellan, ... Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science immunology 6 (56). February 23, 2021.

• TE Sztain, S-H Ahn, et. al with JS McLellan. A glycan gate controls opening of the SARS-CoV-2 spike protein. bioRxiv 2021.02.15.431212; DOI: doi.org/10.1101/2021.02.15.431212

• AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae PloS one 16 (2), e0246803132021.

• Y Huang, AW Nguyen, C-L Hsieh,  R Silva, OS Olaluwoye, RE Wilen, TS Kaoud, LR Azouz, AN Qerqez, KC Le, AL Bohanon,AM DiVenere, Y Liu, AG Lee, D Amengor, KN Dalby, y S D’Arc, JS McLellan, JA Maynard. Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses. bioRxiv 2021.01.31.428824 DOI: doi.org/10.1101/2021.01.31.428824 (Preprint). Commentary [link]

• CG Rappazzo, et. al with J McLellan. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. January 25, 2021.

• S Bhadra, AC Maranhao, I Paik, AD Ellington. A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production. Bio-protocol 11 (2), e3898-e3898202021. Jan 20, 2021.

• Z Ku, X Xie, E Davidson, X Ye, H Su, VD Menachery, Y Li, Z Yuan, ...JS McLellan, ... Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature communications 12 (1), 1-13. Janurary 20, 2021.

• X Wang, Z Du, KE Johnson, SJ Fox, M Lachmann, JS McLellan, LA Meyers. The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US. medRxiv. January 18, 2021. DOI: doi.org/10.1101/2021.01.18.21250071.

• JD Gollihar, JS McLellan, DR Boutz, J Goike, A Horton, EC Gardner, F Bartzoka, N Wang, K Javanmardi, A Herbert, S Abbasi, R Renberg, MJ Johanson, JA Cardona, T Segall-Shapiro, L Zhou, RH Nissly, A Gontu, M Byrom, AC Maranhao, AM Battenhouse, V Gejji, L Soto-Sierra, ER Foster, SL Woodard, ZL Nikolov, J Lavinder, WN Voss, A Annapareddy, GC Ippolito, AD Ellington, EM Marcotte, I J Finkelstein, RA Hughes, JM Musser, SV Kuchipudi, V Kapur, G Georgiou, JM Dye. Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality. bioRxiv. January 1, 2021.

• BL Innis, LD Mercer, JA White, R Scharf, R Hjorth, S Lamola, ...JS McLellan, ... Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase … medRxiv. January 1, 2021.

• AR Shiakolas, N Johnson, KJ Kramer, N Suryadevara, D Wrapp, ... JS McLellan, ... Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking. bioRxiv. January 1, 2021.

• P Kaplonek, C Wang, Y Bartsch, S Fischinger, MJ Gorman, K Bowman, ...JS McLellan, ... Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv. January 1, 2021.

• PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ...JS McLellan, ...Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv. January 1, 2021.

• LM Bobay, AC O'Donnell, and H Ochman (2021) Recombination events are concentrated in the spike protein region of Betacoronaviruses. PLoS Genet. December 17,2020. 16(12):e1009272. DOI: 10.1371/journal.pgen.1009272.

• P Pino, J Kint, D Kiseljak, V Agnolon, G Corradin, AV Kajava, P Rovero, ... JS McLellan, ... Trimeric SARS-CoV-2 spike proteins produced from CHO cells in bioreactors are high-quality antigens. Processes 8 (12), 1539. November 25, 2020.

• R Melero, COS Sorzano, B Foster, JL Vilas, M Martínez, R Marabini, ... JS McLellan, ... Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures. IUCrJ 7 (6). November 1, 2020.

• A Maranhao, S Bhadra, I Paik, D Walker, AD Ellington. An improved and readily available version of Bst DNA Polymerase for LAMP, and applications to COVID-19 diagnostics. medRxiv. October 5, 2020. DOI: doi.org/10.1101/2020.10.02.2020335

• L Casalino, Z Gaieb, JA Goldsmith, CK Hjorth, AC Dommer, AM Harbison, ... JS McLellan, ... Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein, ACS Central Science 6 (10), 1722-1734. September 23, 2020.

• SW Long, et. al. with J Gollihar, JS McLellan, C-W Chou, K Javanmardi, IJ. Finkelstein, J Musser. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. medRxiv. September 22, 2020. DOI: doi.org/10.1101/2020.09.22.20199125

• KB Ragan, S Bhadra, JH Choi, D Towers, CS Sullivan, and AD Ellington. 9/17/2020. “Comparison of media and standards for SARS-CoV-2 RT-qPCR without prior RNA preparation.” medRxiv. DOI: doi.org/10.1101/2020.08.01.20166173. (Preprint)

• E Salazar, et. al. with D Towers, JJ Lavinder, GC Ippolito. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization. The Journal of Clinical Investigation. September 10, 2020. DOI: doi.org/10.1172/JCI141206.

• KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... JS McLellan, ... SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586 (7830), 567-571. August 5, 2020.

• W-S Choi, P He, A Pothukuchy, J Gollihar, AD Ellington, W Yang. How a B family DNA polymerase has been evolved to copy RNA. Proceedings of the National Academy of Sciences. August 17, 2020. DOI: 10.1073/pnas.2009415117

• C-l Hsieh, JA Goldsmith, et. al (J Lavinder, G Ipplito, J Maynard, I Finkelstein and J McLellan). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. July 23, 2020. DOI: 10.1126/science.abd0826

• BA Purnell, V Gradinaru, M Mbow, B Lell, SP Jochems, B Cisse, S Mboup, ... JS McLellan, ... Modeling coronavirus infection. Science 369 (6504), 640-640. July 8, 2020.

• S Bhadra, AC Maranhao, AD Ellington. A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production. bioRXiv. July 6, 2020. DOI: doi.org/10.1101/2020.03.29.013342

• CD. Swaim, LA Canadeo, KJ Monte, S Khanna, DJ Lenschow, JM Huibregtse. Modulation of Extracellular ISG15 Signaling by Pathogens and Viral Effector Proteins. Cell Reports. Vol. 31, Iss. 11. June 16, 2020. DOI: doi.org/10.1016/j.celrep.2020.107772

• AZ Wec, D Wrapp, et. al., with JS McLellan. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. June 15, 2020. DOI: doi.org/10.1126/science.abc7424.

• E Salazar, et al. with G Ippolito. Treatment of COVID-19 Patients with Convalescent Plasma. The American Journal of Pathology. (In Press) DOI: doi.org/10.1016/j.ajpath.2020.05.014

• Z Du, C Nugent, AP Galvani, RM Krug & LA Meyers. Modeling mitigation of influenza epidemics by baloxavir. Nature Communications. June 2, 2020.DOI: doi.org/10.1038/s41467-020-16585-y

• S Bhadra, AC Maranhao, AD Ellington. One enzyme reverse transcription qPCR using Taq DNA polymerase. bioRXiv. May 30, 2020. DOI: doi.org/10.1101/2020.05.27.120238.

• Y Watanabe, ZT Berndsen, J Raghwani, GE Seabright, JD Allen, ...  JS McLellan ...Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nature communications 11 (1), 1-10. May 27, 2020.

• T Smith, A Patel, S Ramos, et al. with J McLellan. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 11, 260. May 20, 2020. DOI: doi.org/10.1038/s41467-020-16505-0.

• JH Choi, HM Woo, T Lee, S Lee, SM Shim, WJ Park, JS Yang, JA Kim, ... JS McLellan ... Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS One 15 (5), e0232757. May 8, 2020.

• D Wrapp, D De Vlieger, KS. Corbett, GM Torres, N Wang, W Van Breedam, K Roose, L van Schie, VIB-CMB COVID-19 Response Team, M Hoffmann, S Pöhlmann, BS Graham, N Callewaert, B Schepens, X Saelens, and JS McLellan. Structural Basis for Potent Neutralization of Betacoronaviruses. Cell. May 5, 2020. DOI: 10.1016/j.cell.2020.04.031

• S Bhadra, TE Riedel, S Lakhotia, ND Tran, AD Ellington. High-surety isothermal amplification and detection of SARS-CoV-2, including with crude enzymes. April 14, 2020. DOI: doi.org/10.1101/2020.04.13.03994

• S Bhadra, AC Maranhao, and AD Ellington. A one-enzyme RT-qPCR assay for SARS-CoV-2, and procedures for reagent production. March 31, 2020. DOI: doi.org/10.1101/2020.03.29.013342

• CR Wells, P Sah, SM Moghadas, A Pandey, A Shoukat, Y Wang, Z Wang , LA Meyers, BH Singer, AP Galvani. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proceedings of the National Academy of Sciences. 2020 Mar 31;117(13):7504-9.

• Y Watanabe, JD Allen, D Wrapp, JS McLellan, M Crispin. Site-specific analysis of the SARS-CoV-2 glycan shield. March 28, 2020. DOI: doi.org/10.1101/2020.03.26.010322

• Z Du, C Nugent, BJ Cowling, LA Meyers. Hundreds of severe pediatric COVID-19 infections in Wuhan prior to the lockdown. medRxiv. 2020 Mar 27.

• CO Buckee, et. al., with LA Meyers. Aggregated mobility data could help fight COVID-19. Science. March 23, 2020. DOI: 10.1126/science.abb8021

• Z Du, Xiaoke Xu, Y Wu, L Wang, BJ Cowling, and LA Meyers. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerging Infectious Diseases. June, 2020. [Originally published March 19, 2020]. DOI: doi.org/10.3201/eid2606.200357

• D Wrapp, N Wang, KS Corbett, JA Goldsmith, C-Lin Hsieh, O Abiona, BS Graham, JS McLellan. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. March 13, 2020: 1260-1263. DOI: 10.1126/science.abb2507.

• TRF Smith, A Patel, S Ramos, D Elwood, X Zhu, J Yan, M Yang, ... JS McLellan,... Rapid development of a synthetic DNA vaccine for COVID-19. Nature Communication 11, Article number: 2601. March 3, 2020.

• Z Du, L Wang, S Chauchemez, X Xu, X Wang, BJ Cowling, et al. Risk for transportation of 2019 novel coronavirus disease from Wuhan to other cities in China. Emerg Infect Diseases. May 2020 [Originally published online Feb. 13, 2020]. DOI: doi.org/10.3201/eid2605.200146

• AR Shiakolas, KJ Kramer, D Wrapp, SI Richardson, A Schäfer, S Wall, ... JS McLellan,... Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions. bioRxiv. January 1, 2020.

• CG Rappazzo, VT Longping, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... JS McLellan,...  An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19. bioRxiv. January 1, 2020.

• BE Jones, PL Brown-Augsburger, KS Corbett, K Westerndorf, J Davies, ... JS McLellan,... LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. January 1, 2020.

LCID Affiliates' Papers
In scientific journals, preprints, etc.

• SJ Fox, K Johnson, B Owirodu, ME Leung, D Walkes, LA Meyers. COVID-19 risk assessment for public events. The University of Texas COVID-19 Modeling Consortium. May 9, 2022.

• M Audirac, M Tec, LA Meyers, S Fox, C Zigler. Impact of the Timing of Stay-at-Home Orders and Mobility Reductions on First-Wave COVID-19 Deaths in US Counties. American Journal of Epidemiology 191 (5), 900-907. May 5, 2022.

• Z Du, Y Bai, L Wang, JL Herrera-Diestra, Z Yuan, R Guo, BJ Cowling, LA Meyers, P Holme. Optimizing COVID-19 surveillance using historical electronic health records of influenza infections. PNAS Nexus. Apr 14, 2022.

• EY Cramer, EL Ray, VK Lopez, J Bracher, A Brennen, ... LA Meyers... Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States. Proceedings of the National Academy of Sciences 119 (15), e2113561119. Apr 8, 2022.

• Z Du, L Wang, Y Bai, X Wang, A Pandey, MC Fitzpatrick, M Chinazzi, ... LA Meyers. Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. The Lancet Regional Health-Americas 8, 100182. Apr 1, 2022.

• Z Du, SJ Fox, T Ingle, MP Pignone, LA Meyers. Projecting the Combined Health Care Burden of Seasonal Influenza and COVID-19 in the 2020–2021 Season. MDM policy & practice 7 (1), 23814683221084631. Mar 8, 2022.

• SJ Fox, M Lachmann, M Tec, R Pasco, S Woody, Z Du, X Wang, TA Ingle, ... LA Meyers. Real-time pandemic surveillance using hospital admissions and mobility data. Proceedings of the National Academy of Sciences 119 (7), e2111870119. Feb 1, 2022.

• A Bouchnita, SJ Fox, M Lachmann, GG Herrera-Diestra, LA Meyers. Omicron scenario projections for the Austin-Round Rock MSA. The University of Texas COVID-19 Modeling Consortium. Jan 25, 2022.

• K Bi, JL Herrera-Diestra, Y Bai, Z Du, L Wang, G Gibson, M Johnson-Leon, ... LA Meyers. The risk of SARS-CoV-2 Omicron variant emergence in low and middle-income countries (LMICs). medRxiv. Jan 14, 2022.

• A Bouchnita, SJ Fox, JLHDM Lachmann, GG Herrera-Diestra, LA Meyers. COVID-19 Scenario Projections: The Emergence of Omicron in the US-January 2022. The University of Texas COVID-19 Modeling Consortium. Jan 6, 2022.

• A Bouchnita, SJ Fox, M Lachmann, JL Herrera-Diestra, G Gibson, LA Meyers. COVID-19 Scenario Projections: The Emergence of Omicron in the US. December 16, 2021. The University of Texas COVID-19 Modeling Consortium.

• KE Johnson, S Woody, M Lachmann, SJ Fox, J Klima, TS Hines, LA Meyers. Real-Time Projections of SARS-CoV-2 B.1.1.7 Variant in a University Setting, Texas, USA. Emerging Infectious Diseases. December, 2021. 27(12):3188-3190. DOI: 10.3201/eid2712.210652.

• N Arslan, DP Morton, J Pichette, D Walkes, and LA Meyers. Projections for Austin’s COVID-19 Staged Alert System, Incorporating Reported Cases as Additional Indicator. November 17, 2021. The University of Texas COVID-19 Modeling Consortium.

• SM Moghadas, P Sah, A Shoukat, LA Meyers, AP Galvani. Population Immunity Against COVID-19 in the United States. Annals of Internal Medicine.  November 2021. DOI: 10.7326/M21-2721.

• R Pasco, M Lachmann, SJ Fox, LA Meyers. Mitigating COVID-19 in schools with facemasks and proactive testing. September 14, 2021. The University of Texas COVID-19 Modeling Consortium.

• KE Johnson, R Pasco, S Woody, M Lachmann, D Bhavnani, J Klima, SJ Fox, LA Meyers. COVID-19 projections for the reopening of the University of Texas at Austin in fall 2021. August 2021. The University of Texas COVID-19 Modeling Consortium

• M Lachmann, A Bouchnita, S Woody, R Pasco, M Johnson-Leon, K Johnson, SJ Fox, LA Meyers. COVID-19 scenario projections for Austin, Texas –– July 2021. July 19, 2021. The University of Texas COVID-19 Modeling Consortium.

• Z Du, L Wang,Y Bai, X Wang, A Pandey, M Chinazzi, A Pastore y Piontti, N Hupert, M Lachmann, A Vespignani, AP Galvani, BJ Cowling, LA Meyers. Cost Effective Proactive Testing Strategies During COVID-19 Mass Vaccination: A Modelling Study. The Lancet. July 1, 2021.

• TA Ingle, M Morrison, X Wang, T Mercer, V Karman, S Fox, LA Meyers. Projecting COVID-19 isolation bed requirements for people experiencing homelessness. Plos One. May 12, 2021. DOI: doi.org/10.1371/journal.pone.0251153

• N Arslan, O Sürer, DP Morton, H Yang, M Lachmann, S Woody, SJ Fox, and LA Meyers. COVID-19 alert stages, healthcare projections and mortality patterns in Austin, Texas, May 2021. May 5, 2021. The University of Texas COVID-19 Modeling Consortium.

• S Woody, E Javan, K Johnson, R Pasco, M Johnson León, M Lachmann, SJ Fox, and LA Meyers. Spatial distribution of COVID-19 infections and vaccinations in Austin, Texas. April 12, 2021. The University of Texas COVID-19 Modeling Consortium.

• Z Du, L Wang, B Yang, ST Ali, TK Tsang, S Shan, P Wu, EHY Lau, BJ Cowling, and LA Meyers. Risk for international importations of variant SARS-CoV-2 originating in the United Kingdom. Emerging infectious diseases 27, no. 5. May 5, 2021.

• S Stockmaier, N Stroeymeyt, EC Shattuck, DM Hawley, LA Meyers, and DI Bolnick. Infectious diseases and social distancing in nature. Science. 371, no. 6533. March 5, 2021. DOI: 10.1126/science.abc8881.

• Z Du, A Pandey, Y Bai, MC Fitzpatrick, M Chinazzi, AP y Piontti, M Lachmann, A Vespignani, BJ Cowling, AP Galvani, and LA Meyers, 2021. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. The Lancet Public Health, 6(3), pp.e184-e191. March, 2021. DOI: doi.org/10.1016/S2468-2667(21)00002-5

• C Matsui, KE Johnson, R Pasco, M Lachmann, SJ Fox, LAl Meyers. COVID-19 Campus Introduction Risks for Spring 2021 at the University of Texas at Austin. January 29, 2021. The University of Texas COVID-19 Modeling Consortium.

• E Javan, EKushnereit, B Betke, S Woody, R Pasco, K Pierce, K Johnson, M Johnson-León, M Lachmann, SJ Fox, LA Meyers. Heterogeneous burden of the COVID-19 pandemic in Central Texas. January 27, 2021.

• H Yang, M Lachmann, Ö Sürer, SJ Fox, DP Morton, LA Meyers. Projecting Need for a COVID-19 Alternate Care Site (ACS) in Austin. Jan. 8, 2021

• M Lachmann, S Fox, and LA Meyers. Potential Impact of Holiday Gatherings on COVID-19 Hospitalizations in Austin. Dec. 23, 2020.

• M Lachmann, SJ Fox, M Tec, R Pasco, Z Du, S Woody, M Dahan, K Gaither, K Pierce, J Scott, G Wells, LA Meyers. Texas Trauma Service Area (TSA) COVID-19 transmission estimates and healthcare projections - Updated Oct. 20, 2020. Oct. 20, 2020.

• X Wang, Z Du, G Huang, RF Pasco, SJ Fox, AP Galvani, M Pignone, SC Johnston, and LA Meyers. Effects of Cocooning on Coronavirus Disease Rates after Relaxing Social Distancing. Emerging Infectious Diseases. Dec. 2020 (Posted online September 21, 2020). DOI: 10.3201/eid2612.201930

• S Risanger, B Singh, D Morton, LA Meyers. Selecting Pharmacies for COVID-19 Testing to Ensure Access. medRxiv. September 18, 2020. DOI: doi.org/10.1101/2020.09.17.20185090

• C Matsui, K Johnson, R Pasco, M Lachmann, SJ Fox, LA Meyers. COVID-19 Campus Introduction and Gathering Risks for Reopening the University of Texas at Austin. August 20, 2020. DOI: doi.org/10.15781/aa7a-0c58

• M Lachmann, SJ Fox, M Tec, R Pasco, M Johnson, J Lu, Z Du, S Woody, J Starling, M Dahan, K Gaither, K Pierce, J Scott, G Wells, LA Meyers. Texas Trauma Service Area (TSA) COVID-19 transmission estimates and healthcare projections: August 25, 2020. Updated after a presentation on August 19, 2020. DOI: doi.org/10.15781/tj6d-dm41

• Z Du, E Javan, C Nugent, BJ Cowling, LA Meyers. Using the COVID-19 to influenza ratio to estimate early pandemic spread in Wuhan, China and Seattle, US. August 12, 2020. DOI: 10.1016/j.eclinm.2020.100479

• M Lachmann, SJ Fox, M Tec, R Pasco, M Johnson, J Lu, Z Du, S Woody, J Starling, M Dahan, K Gaither, K Pierce, J Scott, G Wells, LA Meyers. Texas Trauma Service Area (TSA) COVID-19 transmission estimates and healthcare projections: August 1, 2020. August 1, 2020.

• SJ Fox, M Lachmann, LA Meyers. Risks of COVID-19 Introductions as Schools Reopen. Presented to The New York Times July 31, 2020.

• D Duque, DP Morton, B Singh, Z Du, R Pasco, LA Meyers. Timing social distancing to avert unmanageable COVID-19 hospital surges. Proceedings of the National Academy of Sciences. July 29 2020. DOI: 10.1073/pnas.2009033117

• SJ Fox, M Lachmann, LA Meyers. COVID-19 Campus Introduction Risks for School Reopenings. Presented on July 22, 2020.

• X Wang, RF Pasco, Z Du, M Petty, SJ Fox, AP Galvani, et al. Impact of social distancing measures on coronavirus disease healthcare demand, central Texas, USA. Emerg Infect Dis. 2020 Oct. DOI: doi.org/10.3201/eid2610.201702

• M Tec, M Lachmann, SJ Fox, R Pasco, S Woody, J Starling, M Dahan, K Gaither, J Scott, LA Meyers. Austin COVID-19 transmission estimates and healthcare projections. Presented on July 15, 2020. DOI: doi.org/10.15781/jaa9-ff48

• SJ Fox, R Pasco, M Tec, Z Du, M Lachmann, J Scott, LA Meyers. The impact of asymptomatic COVID-19 infections on future pandemic waves. medRxiv. June 22, 2020.

• H Yang, D Duque, Ö Sürer, DP Morton, R Pasco, K Pierce, SJ Fox, LA Meyers. Staged Strategy to Avoid Hospital Surge and Preventable Mortality, while Reducing the Economic Burden of Social Distancing Measures. Presented on June 15, 2020. DOI: doi.org/10.15781/hmf9-cx87

• LA Meyers, Z Du, RM Krug. Hoping for a COVID-19 antiviral that limits virus spread. Nature Microbiology. June 2, 2020.

• Z Du, C Nugent, AP Galvani, RM Krug & LA Meyers. Modeling mitigation of influenza epidemics by baloxavir. Nature Communications. June 2, 2020. DOI: doi.org/10.1038/s41467-020-16585-y

• Z Du, X Xu, L Wang, SJ Fox, BJ Cowling, AP Galvani & LA Meyers. Proactive social distancing mitigates COVID-19 outbreaks within a month across 58 mainland China cities. Emerging Infectious Disease. 

• D Duque, M Tec, DP Morton, J Scott, H Yang, R Pasco, K Pierce, SJ Fox, M Pignone, P Hudson, and LA Meyers. Staged Strategy to Avoid Hospital Surge and Preventable Mortality, while Reducing the Economic Burden of Social Distancing Measures. Presented to the city of Austin and Travis County on May 18, 2020. DOI: doi.org/10.15781/xw18-9m2

• D Duque, DP Morton, B Singh, Z Du, R Pasco, LA Meyers, COVID-19: How to Relax Social Distancing If You Must. medRxiv. May 5, 2020.

• K Pierce, E Ho, X Wang, R Pasco, Z Du, S Fox, G Zynda, J Song, LA Meyers. COVID-19 Healthcare Demand Projections: Beaumont-Port Arthur MSA, Texas. April 29, 2020. DOI: doi.org/10.15781/j8dw-ev41

• K Pierce, E Ho, X Wang, R Pasco, Z Du, S Fox, G Zynda, J Song, LA Meyers. COVID-19 Healthcare Demand Projections: Houston-The Woodlands-Sugar Land MSA, Texas. April 28, 2020. DOI: doi.org/10.15781/z822-gr62

• D Duque, DP Morton, B Singh, Z Du, R Pasco, LA Meyers. COVID-19 in Austin, Texas: Averting healthcare surges while relaxing social distancing. April 28, 2020. DOI: doi.org/10.15781/dvm2-w474

• X Wang, Z Du, G Huang, S Fox, LA Meyers. COVID-19 in Austin, Texas: Relaxing Social Distancing Measures. April 23, 2020. DOI: doi.org/10.15781/cytm-ev55

• X Wang, R Pasco, K Pierce, Z Du, S Fox, LA Meyers. COVID-19 Healthcare Demand Projections: Austin, Texas: April 20, 2020. Posted online April 21, 2020. DOI: doi.org/10.15781/503k-c81

• R Pasco, X Wang, Z Du, SJ Fox, LA Meyers. COVID-19 in Austin, Texas: Epidemiological Assessment of Grocery Shopping. April 17, 2020. DOI: doi.org/10.15781/n0ha-3c71

• S Woody, M Tec, M Dahan, K Gaither, M Lachmann, SJ Fox, LA Meyers, and J Scott. Projections for first-wave COVID-19 deaths across the U.S. using social-distancing measures derived from mobile phones. April 17, 2020. DOI: doi.org/10.15781/ry5m-r054

• X Wang, Z Du, R Pasco, K Pierce, M Petty, SJ Fox, M Pignone, C Johnston, LA Meyers.  COVID-19 Healthcare Demand Projections: Austin, Texas: April 6, 2020. April 6, 2020. DOI: doi.org/10.15781/fezq-c612

• R Pasco, Z Du, X Wang, M Petty, SJ Fox, LA Meyers. COVID-19 in Austin, Texas: Epidemiological Assessment of Construction Work. April 5, 2020. DOI: doi.org/10.15781/hzem-6s96

• E Javan, SJ Fox, LA Meyers. Probability of current COVID-19 outbreaks in all US counties. April 3, 2020. DOI: doi.org/10.15781/4y2y-z972

• Z Du, X Wang, R Pasco, M Petty, SJ Fox, and LA Meyers. COVID-19 Healthcare Demand Projections: 22 Texas Cities. First published: March 31, 2020; updated April 5, 2020. DOI: doi.org/10.15781/tmvs-g131

• SM Moghadas, A Shoukat, MC Fitzpatrick, CR Wells, P Sah, A Pandey, JD Sachs, Z Wang, LA Meyers, BH Singer, AP Galvani. Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proceedings of the National Academy of Sciences. 2020 Apr 3.

• CR Wells, P Sah, SM Moghadas, A Pandey, A Shoukat, Y Wang, Z Wang, LA Meyers, BH Singer, AP Galvani. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proceedings of the National Academy of Sciences. 2020 Mar 31;117(13):7504-9.

• Z Du, C Nugent, BJ Cowling, LA Meyers. Hundreds of severe pediatric COVID-19 infections in Wuhan prior to the lockdown. medRxiv. 2020 Mar 27.

• R Pasco, X Wang, M Petty, Z Du, SJ Fox, M Pignone, C Johnston, and LA Meyers. COVID-19 Healthcare Demand Projections: Austin, Texas: March, 2020. March 26, 2020. DOI: doi.org/10.15781/1dqt-gv36